Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Pharmacoeconomics|September 13, 2014
Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisalJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Health Technology Assessment (Winchester, England)|April 22, 2015
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysisJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Stroke|October 9, 2010
Discarding heparins as treatment for progressive stroke in Sweden 2001 to 2008Marie Eriksson, Anna Stecksén, Eva-Lotta Glader, et al.
Cerebrovascular Diseases (Basel, Switzerland)|May 27, 2010
Trends in baseline patient characteristics during the years 1995-2008: observations from Riks-Stroke, the Swedish Stroke RegisterPeter Appelros, Fredrik Jonsson, Kjell Asplund, et al.
Cerebrovascular Diseases (Basel, Switzerland)|December 21, 2013
Trends in stroke treatment and outcome between 1995 and 2010: observations from Riks-Stroke, the Swedish stroke registerPeter Appelros, Fredrik Jonsson, Signild Åsberg, et al.
Pharmacoeconomics|April 12, 2013
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisalJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Stroke|June 5, 2010
Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke RegisterSignild Asberg, Karin M Henriksson, Bahman Farahmand, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|March 27, 2015
Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST)Astrid G Hornslien, Else C Sandset, Jannicke Igland, et al.
Health Technology Assessment (Winchester, England)|January 15, 2020
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluationNigel Fleeman, Rachel Houten, Adrian Bagust, et al.
Pharmacoeconomics|March 20, 2017
Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Adrian Bagust, Angela Boland, et al.
Pageof 8